Search results
Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval
Bloomberg Law· 12 hours ago... pharmaceutical manufacturer known for its sleep medicines will argue Friday before a federal district court that the FDA violated an orphan drug law when it approved a rival product. will take to the US District Court for the District...Food and Drug Administration on whether the agency violated...
Earnings call: Aquestive Therapeutics highlights progress and outlook for 2024
Investing.com· 16 hours agoAquestive Therapeutics (NASDAQ: NASDAQ: AQST ) has shared an optimistic update during its...
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC...
FOX40 Sacramento· 1 day agoFood and Drug Administration (FDA) has granted Breakthrough Therapy designation to delpacibart etedesiran (AOC 1001), the company's lead clinical development ...
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up
Zacks via Yahoo Finance· 5 hours agoTEVA reports mixed first-quarter results, missing estimates for earnings but beating the same for...
Q1 2024 Vanda Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 10 hours agoFinally, an update on tradipitant. Tradipitant, our neurokinin-1 receptor antagonist is currently being developed for the treatment of gastroparesis with a New Drug Application ...
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner
Ram Page· 23 hours agoRyan Confer Appointed Genprex President and CEO and to its Board of Directors
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and...
WTNH-TV New Haven· 1 day agoSyndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an...
Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With...
Digital Journal· 9 hours agoRegistrational phase 3 clinical trials of Biodexa's (NASDAQ:BDRX) candidate eRapa are expected to start first quarter next year. The candidate was developed with private funds and acquired by ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 1 day agoAlterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
WTNH-TV New Haven· 3 days agoA host-directed and potentially broad acting twice-daily oral, small molecule, opaganib is in development for multiple indications, including COVID-19, acute respiratory distress syndrome, oncology ...
